ClinVar Miner

Submissions for variant NM_000518.5(HBB):c.92+1G>A (rs33971440)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000508514 SCV000603901 pathogenic not specified 2017-03-06 criteria provided, single submitter clinical testing
Counsyl RCV000020340 SCV000678025 pathogenic beta Thalassemia 2015-10-28 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics,Eurofins Clinical Diagnostics RCV000390929 SCV000700731 pathogenic not provided 2017-01-13 criteria provided, single submitter clinical testing
Fulgent Genetics,Fulgent Genetics RCV000763254 SCV000893891 pathogenic Beta-thalassemia, dominant inclusion body type; Fetal hemoglobin quantitative trait locus 1; Heinz body anemia; Hb SS disease; alpha Thalassemia; Susceptibility to malaria; beta Thalassemia; METHEMOGLOBINEMIA, BETA TYPE; Erythrocytosis 6, familial 2018-10-31 criteria provided, single submitter clinical testing
GeneDx RCV000390929 SCV000329826 pathogenic not provided 2018-12-22 criteria provided, single submitter clinical testing The c.92+1G>A pathogenic variant in the HBB gene has been reported previously in association with beta-thalassemia (Faustino et al., 1992). This splice site variant destroys the canonical splice donor site in intron 1, resulting in a frameshift that removes the translation initiator Methionine codon. The c.92+1G>A variant is observed in 5/66,726 (0.0075%) alleles from individuals of non-Finnish European background in the ExAC dataset (Lek et al., 2016). We interpret c.92+1G>A as a pathogenic variant.
GeneReviews RCV000020340 SCV000040716 pathogenic beta Thalassemia 2015-05-14 no assertion criteria provided literature only
Invitae RCV000390929 SCV000934096 pathogenic not provided 2018-08-27 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 1 of the HBB gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is present in population databases (rs33971440, ExAC 0.009%). This variant has been observed in several individuals affected with HBB-related conditions (PMID: 28391758, 28366028, 2200760). This variant is also known in the literature as IVS-I-1(G>A). ClinVar contains an entry for this variant (Variation ID: 15436). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in HBB are known to be pathogenic (PMID: 23637309). For these reasons, this variant has been classified as Pathogenic.
OMIM RCV000016694 SCV000036964 pathogenic beta^0^ Thalassemia 1982-04-15 no assertion criteria provided literature only
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000390929 SCV000601324 pathogenic not provided 2017-07-10 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.